Suprathreshold duloxetine for treatment-resistant depression, anorexia nervosa binge-purging type, and obsessive-compulsive disorder: a case report.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Innovations in Clinical Neuroscience

• Publication date

  2012-03-01

• Fields of study

  Medicine, Psychology

• Identifiers
  PMID 22567604PMCID PMC3342990
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Efficacy and safety of duloxetine 60 mg and 120 mg daily in patients hospitalized for severe depression: a double-blind randomized trial.

  2011cited by this paper
• Duloxetine

  2011cited by this paper
• Successful duloxetine treatment of a binge eating disorder: a case report

  2010cited by this paper
• Comparison of SSRIs and SNRIs in major depressive disorder: a meta‐analysis of head‐to‐head randomized clinical trials

  2010cited by this paper
• Desvenlafaxine in major depressive disorder: an evidence-based review of its place in therapy

  2009cited by this paper
• High-dose duloxetine for treatment-resistant obsessive-compulsive disorder: a case report with sustained full remission.

  2009cited by this paper
• The use of duloxetine in chronic bulimia nervosa: a case report.

  2009cited by this paper
• Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs.

  2008cited by this paper
• Switching from serotonin reuptake inhibitors to duloxetine in patients with resistant obsessive compulsive disorder: a case series

  2008cited by this paper
• Efficacy of Duloxetine and Selective Serotonin Reuptake Inhibitors: Comparisons as Assessed by Remission Rates in Patients With Major Depressive Disorder

  2007cited by this paper
• Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents.

  2007cited by this paper
• QT Effects of Duloxetine at Supratherapeutic Doses: A Placebo and Positive Controlled Study

  2007cited by this paper
• Practice guideline for the treatment of patients with obsessive-compulsive disorder.

  2007cited by this paper
• Duloxetine

  2007cited by this paper
• Serotonin-norepinephrine reuptake inhibitors in the treatment of obsessive-compulsive disorder: A critical review.

  2006cited by this paper
• SNRIs: The Pharmacology, Clinical Efficacy, and Tolerability in Comparison with Other Classes of Antidepressants

  2005cited by this paper

• Efficacy of Supratherapeutic Duloxetine Combined With Cognitive-Behavioral Therapy in Severe Treatment-Resistant Obsessive-Compulsive Disorder With Comorbid Depression: A Case Report

  2024influential citation
• Duloxetine usage in depression

  2021cites this paper
• Drug Treatment of Body Image Disturbance in Mental Disorders

  2018cites this paper
• Off‐Label Prescribing by Psychiatrists: What is the Practitioner's Liability?

  2015cites this paper
• Psychopharmacological options for adult patients with anorexia nervosa

  2015cites this paper
• Die Rolle des Visfatin in der Neurobiologie der Anorexia nervosa

  2015cites this paper
• An updated review of antidepressants with marked serotonergic effects in obsessive–compulsive disorder

  2014cites this paper
• A retrospective review of isolated duloxetine-exposure cases

  2013cites this paper
• Perplexities of treatment resistence in eating disorders

  2013cites this paper
• Efficacy and safety of duloxetine 60 mg and 120 mg daily in patients hospitalized for severe depression: a double-blind randomized trial.

  2011cites this paper